Pelthos TherapeuticsPTHS

13F holders, Q1 2026 (March 31)
17holders +2
3new positions
2sold out
$21.01avg. 13F price*

At the end of Q1 2026, 17 institutions reported holding Pelthos Therapeutics Inc. (PTHS) in their 13F filings, up 2 from Q4 2025. 3 opened new positions and 2 sold out. The largest holders were Murchinson Ltd. ($6.2M), Ikarian Capital, LLC ($5.4M) and Vanguard Capital Management LLC ($2.0M).

Company
Pelthos Therapeutics Inc.
CUSIP
171126204
Latest filing quarter
Q2 2026

History

Number of 13F holders

0510152025 Q3 2025: 14Q3 2025Q4 2025: 15Q4 2025Q1 2026: 17Q1 2026Q2 2026: 24Q2 2026

Total Exit/New Position Q4 2025 → Q1 2026

InstitutionsTotal Value
New Positions3$1K
Exits2$343K

All 13F filers, Q4 2025 → Q1 2026: 23,949 shares bought and 38,887 shares sold, net −14,938 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 17 holders

Murchinson Ltd. 2.51% Add +2.4% 296,314 $6.2M
Ikarian Capital, LLC 0.77% Add +0.3% 256,598 $5.4M
Vanguard Capital Management LLC 0.00% — 93,093 $2.0M
Boothbay Fund Management, LLC 0.04% Add +1.5% 81,858 $1.7M
J. Goldman & Co LP 0.05% Reduce -35.4% 50,415 $1.1M
Cantor Fitzgerald, L. P. 0.03% Add +18.4% 41,423 $870K
Diadema Partners LP 0.21% Reduce -0.9% 24,773 $520K
Knott David M Jr 0.26% Add +9.3% 21,073 $443K
Geode Capital Management, LLC 0.00% Add +12.2% 15,290 $321K
Pale Fire Capital SE 0.02% Add +59.5% 12,919 $271K
Vanguard Fiduciary Trust Co. 0.00% — 9,817 $206K
Persistent Asset Partners Ltd 0.05% No change 6,007 $126K
Steward Partners Investment Advisory, LLC 0.00% No change 1,910 $40K
UBS Group AG 0.00% Add +76.0% 764 $16K
Farther Finance Advisors, LLC 0.00% New 40 $852
Aspect Partners, LLC 0.00% New 16 $336
Citigroup Inc. 0.00% New 1 $21

"% of holder's portfolio" is PTHS's weight in each manager's 13F, not the share of Pelthos Therapeutics Inc. the manager owns.